Without superiority, it you will struggle with investors, trials, approval,and then convincing doctors to to switch to it.
Everyone can come up with an example, and point to per due, but the FDA processes 10s of thousands of device and drug submissions per year. Most are in cutthroat markets with competitors.
If we are talking about individual company actions or statements, and not products, then the numbers are even worse. There are literally millions of actions associated with a product, and I would again argue that >99.9 are made in the favor of patient interest.
Making a inferior product and scamming your way to profit is an exceedingly rare strategy because it is both extremely difficult execute successfully.
I think it is clear that new product development doesn't prioritize optimal patient benefit, but that is a different topic. It needs to be good enough to sell, then it becomes a question of how good vs how much money.
That isn't even true at non-profits, let alone for profit companies. You seem to have no idea how the world works.
I do think that newer more expensive products provide worse patient outcomes at rates significantly higher than 1 / 1000 times.
However, the comment I objected is discussing "ways to make money" as a pharmacutical company. Which is a generalization that is laughably naive at best. We have plenty of examples of drug companies trying to make money in ways that harm patients from how they fostered the opiod epidemic.